Glaukos Corporation (GKOS)
์๊ฐ์ด์ก: 6.40B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
2309: 78.05M / -- / -- / -- / -2.9%
2306: 80.4M / -- / -- / -- / 8.8%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
2309: -0.63 / -- / -- / -- / 7.4%
2306: -0.68 / -- / -- / -- / 5.6%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass ste...
์๊ฐ์ด์ก: 6.40B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
2309: 78.05M / -- / -- / -- / -2.9%
2306: 80.4M / -- / -- / -- / 8.8%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, MoM)
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
2309: -0.63 / -- / -- / -- / 7.4%
2306: -0.68 / -- / -- / -- / 5.6%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass ste...
#GKOS
Glaukos Announces Second Quarter 2024 Financial Results
https://finance.yahoo.com/news/glaukos-announces-second-quarter-2024-200500691.html
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
https://finance.yahoo.com/news/4-medtech-stocks-beat-forecasts-173200762.html
A Look At The Fair Value Of Glaukos Corporation (NYSE:GKOS)
https://finance.yahoo.com/news/look-fair-value-glaukos-corporation-104904694.html
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
https://finance.yahoo.com/news/earnings-preview-teleflex-tfx-q2-140150561.html
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
https://finance.yahoo.com/news/glaukos-gkos-may-report-negative-140125815.html
Glaukos Announces Second Quarter 2024 Financial Results
https://finance.yahoo.com/news/glaukos-announces-second-quarter-2024-200500691.html
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
https://finance.yahoo.com/news/4-medtech-stocks-beat-forecasts-173200762.html
A Look At The Fair Value Of Glaukos Corporation (NYSE:GKOS)
https://finance.yahoo.com/news/look-fair-value-glaukos-corporation-104904694.html
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
https://finance.yahoo.com/news/earnings-preview-teleflex-tfx-q2-140150561.html
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
https://finance.yahoo.com/news/glaukos-gkos-may-report-negative-140125815.html
Yahoo Finance
Glaukos Announces Second Quarter 2024 Financial Results
ALISO VIEJO, Calif., July 31, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial resultsโฆ
Glaukos Corporation (GKOS)
์๊ฐ์ด์ก: 7.26B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 96.7M / 91.5M / 5.7% / 23.9% / 1.0%
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
2309: 78.05M / -- / -- / -- / -2.9%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: -0.28 / -0.48 / 41.7% / 55.6% / 46.2%
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
2309: -0.63 / -- / -- / -- / 7.4%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject ...
์๊ฐ์ด์ก: 7.26B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: 96.7M / 91.5M / 5.7% / 23.9% / 1.0%
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
2309: 78.05M / -- / -- / -- / -2.9%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2409: -0.28 / -0.48 / 41.7% / 55.6% / 46.2%
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
2309: -0.63 / -- / -- / -- / 7.4%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject ...
#GKOS
Glaukos: Q3 Earnings Snapshot
https://finance.yahoo.com/news/glaukos-q3-earnings-snapshot-212549140.html
Glaukos Announces Third Quarter 2024 Financial Results
https://finance.yahoo.com/news/glaukos-announces-third-quarter-2024-210500148.html
Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result
https://finance.yahoo.com/news/earnings-watch-glaukos-corp-gkos-130140290.html
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
https://finance.yahoo.com/news/masimo-masi-reports-next-week-140109950.html
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://finance.yahoo.com/news/glaukos-gkos-expected-beat-earnings-140112575.html
Glaukos: Q3 Earnings Snapshot
https://finance.yahoo.com/news/glaukos-q3-earnings-snapshot-212549140.html
Glaukos Announces Third Quarter 2024 Financial Results
https://finance.yahoo.com/news/glaukos-announces-third-quarter-2024-210500148.html
Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result
https://finance.yahoo.com/news/earnings-watch-glaukos-corp-gkos-130140290.html
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
https://finance.yahoo.com/news/masimo-masi-reports-next-week-140109950.html
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://finance.yahoo.com/news/glaukos-gkos-expected-beat-earnings-140112575.html
Yahoo Finance
Glaukos: Q3 Earnings Snapshot
GKOS) on Monday reported a loss of $21.4 million in its third quarter. The Aliso Viejo, California-based company said it had a loss of 39 cents per share. Losses, adjusted for amortization costs and costs related to mergers and acquisitions, were 28 centsโฆ
12์ 6์ผ ์ธ์ฌ ๊ธฐ์
๋ฆฌํฌํธ
<๊ธฐ์ ๋ฆฌํฌํธ>
1. Accenture (#ACN)
- Goldman Sachs
- ๊ธ๋ก๋ฒ ์ต๋ IT ์๋น์ค ์ ๊ณต์ ์ฒด๋ก, Buy ๋ฑ๊ธ์ผ๋ก ์ํฅ ์กฐ์ ํ๋ฉฐ ๋ชฉํ๊ฐ $370 -> $420๋ก ์กฐ์
2. Sight Sciences (#SGHT)
- UBS
- ํ์ ์ ์ธ ์๋ฃ๊ธฐ๊ธฐ ๊ธฐ์ ์ผ๋ก, TearCare ์๋ฃจ์ ์ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ๋ผ Buy ๋ฑ๊ธ ์ ๊ท ์์
3. Glaukos (#GKOS)
- UBS
- ๋ น๋ด์ฅ ์น๋ฃ ์๋ฃจ์ ์ ๋ฌธ ๊ธฐ์ ์ผ๋ก, iDose ์๋ฃจ์ ๋งค์ถ ์ฑ์ฅ ๊ธฐ๋์ ํจ๊ป Buy ๋ฑ๊ธ ์ ๊ท ์์
4. Hewlett Packard Enterprise (#HPE)
- Morgan Stanley
- ํด๋ผ์ฐ๋ ์๋ฃจ์ ์ ๊ณต ๊ธฐ์ ์ผ๋ก, Juniper Networks ์ธ์์ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ์ํด Overweight๋ก ์ํฅ ์กฐ์
5. Applied Materials (#AMAT)
- Morgan Stanley
- ์จ์ดํผ ์ ์กฐ ์ฅ๋น ๊ธฐ์ ์ผ๋ก, 2025๋ ์์ฅ ์ง์ถ ๊ฐ์ ์ ๋ง์ผ๋ก Underweight๋ก ๋ฑ๊ธ ํํฅ ์กฐ์
6. Synopsys Inc. (#SNPS)
- KeyBanc Capital Markets
- ์ ์ ์ค๊ณ ์๋ํ ์๋ฃจ์ ์ ๋ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $690๋ก ์ ์ง
7. Synopsys Inc. (#SNPS)
- Piper Sandler
- 2025๋ ๋ณด์์ ๋งค์ถ ์ ๋ง์๋ Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $670 -> $655๋ก ํํฅ ์กฐ์
8. Teva Pharmaceutical Industries (#TEVA)
- Piper Sandler
- ๊ธ๋ก๋ฒ ์ ์ฝ ์ ๋ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ Austedo ํ๋์ฐจ์ด์ฆ ์ฑ์ฅ ๊ธฐ๋
9. Gibson Energy (#GEI)
- BMO Capital
- ์บ๋๋ค ๊ธฐ๋ฐ ์๋์ง ๊ธฐ์ ์ผ๋ก, Gateway Terminal ์์ต ์ฆ๊ฐ ์ ๋ง์ ๋ฐ๋ผ Outperform๋ก ์ํฅ ์กฐ์
10. Ryan Specialty Group (#RYAN)
- Morgan Stanley
- ํน์ ๋ณดํ ์๋ฃจ์ ์ ๊ณต ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ๊ท ์์ํ๋ฉฐ ๋ชฉํ๊ฐ $90 ์ค์
11. Nano-X Imaging (#NNOX)
- Cantor Fitzgerald
- ํ์ ์ ์ธ ์๋ฃ ์์ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, ์์คํ ๋ฐฐ์น ํ๋์๋ ๋ชฉํ๊ฐ $14 -> $11๋ก ํํฅ ์กฐ์
12. PayPal Holdings (#PYPL)
- Barclays
- ๊ธ๋ก๋ฒ ๋์งํธ ๊ฒฐ์ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $92๋ก ๋ณ๋ ์์
13. Hon Hai Precision Industry (#2317)
- JP๋ชจ๊ฑด
- AI ์๋ฒ ์์ฐ ๊ฐ์ธ์ ์ฑ์ฅ ์ ์ฌ๋ ฅ์ ๋ฐ๋ผ Overweight ๋ฑ๊ธ ์ ์ง
14. Republic Services (#RSG)
- BMO Capital
- ํ๊ธฐ๋ฌผ ๊ด๋ฆฌ ์ ๋ ๊ธฐ์ ์ผ๋ก, ์ ๊ธฐ์ฐจ ๋ฐ ์ฌํ์ฉ ์ญ๋ ๊ฐํ์ ๋ฐ๋ผ Outperform๋ก ์ํฅ ์กฐ์
15. Veeva Systems (#VEEV)
- Barclays
- ์๋ช ๊ณผํ ํด๋ผ์ฐ๋ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Clinical Data Management System ๊ณ์ฝ ์ฆ๊ฐ ๊ธฐ๋์ ํจ๊ป ๋ชฉํ๊ฐ $260 -> $275๋ก ์ํฅ ์กฐ์
16. GitLab (#GTLB)
- KeyBanc Capital Markets
- DevSecOps ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Duo SKU ๋ฐ ์์ฅ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ๋ผ ๋ชฉํ๊ฐ $74 -> $80๋ก ์ํฅ ์กฐ์
<์ ๋ต& ๋งคํฌ๋ก ๋ฆฌํฌํธ>
1. Michael Hartnett (๋ฑ ํฌ์ค๋ธ์๋ฉ๋ฆฌ์นด ์ ๋ต๊ฐ)
- ๋ฏธ๊ตญ ์ฃผ์๊ณผ ์ํธํํ์ ์์น์ธ๋ฅผ ๊ณผ์ด ์ํ๋ก ๋ณด๊ณ , S&P 500์ด 2025๋ ์ด ๊ณผ์ ์์น ์ํ์ ์ง๋ฉดํ ๊ฐ๋ฅ์ฑ์ด ์๋ค๊ณ ํ๊ฐ
https://naver.me/FRLlgQHc
(์์ธํ ๋ด์ฉ์ ๋งํฌ ์ฐธ์กฐ)
241206 US ๊ธฐ์ TP ์ ๋ฆฌ
Upgrades
#APP #TEAM #CHWY #FIVE #NFLX #HOOD #CRM #IOT #BRKR #COP #DEO #EXAS #GTES #HPE #ITW #MBLY #MGA #OKTA #ROK #WTW
Downgrades
#ABBV #AEO #ALLY #AMAT #CHWY #CNX #DVN #F #FOUR #FWONA #GRAB #MRVI #NAUT #NCNO #OTIS #PB #PFG #RLMD #ROP #SBRA #SM #VCYT
https://naver.me/5mI8ZwxU
(์์ธํ ๋ด์ฉ์ ๋งํฌ ์ฐธ์กฐ)
<๊ธฐ์ ๋ฆฌํฌํธ>
1. Accenture (#ACN)
- Goldman Sachs
- ๊ธ๋ก๋ฒ ์ต๋ IT ์๋น์ค ์ ๊ณต์ ์ฒด๋ก, Buy ๋ฑ๊ธ์ผ๋ก ์ํฅ ์กฐ์ ํ๋ฉฐ ๋ชฉํ๊ฐ $370 -> $420๋ก ์กฐ์
2. Sight Sciences (#SGHT)
- UBS
- ํ์ ์ ์ธ ์๋ฃ๊ธฐ๊ธฐ ๊ธฐ์ ์ผ๋ก, TearCare ์๋ฃจ์ ์ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ๋ผ Buy ๋ฑ๊ธ ์ ๊ท ์์
3. Glaukos (#GKOS)
- UBS
- ๋ น๋ด์ฅ ์น๋ฃ ์๋ฃจ์ ์ ๋ฌธ ๊ธฐ์ ์ผ๋ก, iDose ์๋ฃจ์ ๋งค์ถ ์ฑ์ฅ ๊ธฐ๋์ ํจ๊ป Buy ๋ฑ๊ธ ์ ๊ท ์์
4. Hewlett Packard Enterprise (#HPE)
- Morgan Stanley
- ํด๋ผ์ฐ๋ ์๋ฃจ์ ์ ๊ณต ๊ธฐ์ ์ผ๋ก, Juniper Networks ์ธ์์ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ์ํด Overweight๋ก ์ํฅ ์กฐ์
5. Applied Materials (#AMAT)
- Morgan Stanley
- ์จ์ดํผ ์ ์กฐ ์ฅ๋น ๊ธฐ์ ์ผ๋ก, 2025๋ ์์ฅ ์ง์ถ ๊ฐ์ ์ ๋ง์ผ๋ก Underweight๋ก ๋ฑ๊ธ ํํฅ ์กฐ์
6. Synopsys Inc. (#SNPS)
- KeyBanc Capital Markets
- ์ ์ ์ค๊ณ ์๋ํ ์๋ฃจ์ ์ ๋ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $690๋ก ์ ์ง
7. Synopsys Inc. (#SNPS)
- Piper Sandler
- 2025๋ ๋ณด์์ ๋งค์ถ ์ ๋ง์๋ Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $670 -> $655๋ก ํํฅ ์กฐ์
8. Teva Pharmaceutical Industries (#TEVA)
- Piper Sandler
- ๊ธ๋ก๋ฒ ์ ์ฝ ์ ๋ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ Austedo ํ๋์ฐจ์ด์ฆ ์ฑ์ฅ ๊ธฐ๋
9. Gibson Energy (#GEI)
- BMO Capital
- ์บ๋๋ค ๊ธฐ๋ฐ ์๋์ง ๊ธฐ์ ์ผ๋ก, Gateway Terminal ์์ต ์ฆ๊ฐ ์ ๋ง์ ๋ฐ๋ผ Outperform๋ก ์ํฅ ์กฐ์
10. Ryan Specialty Group (#RYAN)
- Morgan Stanley
- ํน์ ๋ณดํ ์๋ฃจ์ ์ ๊ณต ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ๊ท ์์ํ๋ฉฐ ๋ชฉํ๊ฐ $90 ์ค์
11. Nano-X Imaging (#NNOX)
- Cantor Fitzgerald
- ํ์ ์ ์ธ ์๋ฃ ์์ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, ์์คํ ๋ฐฐ์น ํ๋์๋ ๋ชฉํ๊ฐ $14 -> $11๋ก ํํฅ ์กฐ์
12. PayPal Holdings (#PYPL)
- Barclays
- ๊ธ๋ก๋ฒ ๋์งํธ ๊ฒฐ์ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Overweight ๋ฑ๊ธ ์ ์งํ๋ฉฐ ๋ชฉํ๊ฐ $92๋ก ๋ณ๋ ์์
13. Hon Hai Precision Industry (#2317)
- JP๋ชจ๊ฑด
- AI ์๋ฒ ์์ฐ ๊ฐ์ธ์ ์ฑ์ฅ ์ ์ฌ๋ ฅ์ ๋ฐ๋ผ Overweight ๋ฑ๊ธ ์ ์ง
14. Republic Services (#RSG)
- BMO Capital
- ํ๊ธฐ๋ฌผ ๊ด๋ฆฌ ์ ๋ ๊ธฐ์ ์ผ๋ก, ์ ๊ธฐ์ฐจ ๋ฐ ์ฌํ์ฉ ์ญ๋ ๊ฐํ์ ๋ฐ๋ผ Outperform๋ก ์ํฅ ์กฐ์
15. Veeva Systems (#VEEV)
- Barclays
- ์๋ช ๊ณผํ ํด๋ผ์ฐ๋ ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Clinical Data Management System ๊ณ์ฝ ์ฆ๊ฐ ๊ธฐ๋์ ํจ๊ป ๋ชฉํ๊ฐ $260 -> $275๋ก ์ํฅ ์กฐ์
16. GitLab (#GTLB)
- KeyBanc Capital Markets
- DevSecOps ์๋ฃจ์ ๊ธฐ์ ์ผ๋ก, Duo SKU ๋ฐ ์์ฅ ์ฑ์ฅ ๊ฐ๋ฅ์ฑ์ ๋ฐ๋ผ ๋ชฉํ๊ฐ $74 -> $80๋ก ์ํฅ ์กฐ์
<์ ๋ต& ๋งคํฌ๋ก ๋ฆฌํฌํธ>
1. Michael Hartnett (๋ฑ ํฌ์ค๋ธ์๋ฉ๋ฆฌ์นด ์ ๋ต๊ฐ)
- ๋ฏธ๊ตญ ์ฃผ์๊ณผ ์ํธํํ์ ์์น์ธ๋ฅผ ๊ณผ์ด ์ํ๋ก ๋ณด๊ณ , S&P 500์ด 2025๋ ์ด ๊ณผ์ ์์น ์ํ์ ์ง๋ฉดํ ๊ฐ๋ฅ์ฑ์ด ์๋ค๊ณ ํ๊ฐ
https://naver.me/FRLlgQHc
(์์ธํ ๋ด์ฉ์ ๋งํฌ ์ฐธ์กฐ)
241206 US ๊ธฐ์ TP ์ ๋ฆฌ
Upgrades
#APP #TEAM #CHWY #FIVE #NFLX #HOOD #CRM #IOT #BRKR #COP #DEO #EXAS #GTES #HPE #ITW #MBLY #MGA #OKTA #ROK #WTW
Downgrades
#ABBV #AEO #ALLY #AMAT #CHWY #CNX #DVN #F #FOUR #FWONA #GRAB #MRVI #NAUT #NCNO #OTIS #PB #PFG #RLMD #ROP #SBRA #SM #VCYT
https://naver.me/5mI8ZwxU
(์์ธํ ๋ด์ฉ์ ๋งํฌ ์ฐธ์กฐ)
Naver
12์ 6์ผ ์ธ์ฌ ๊ธฐ์
& ๊ฒฝ์ ๋ฆฌํฌํธ
Glaukos Corporation (GKOS)
์๊ฐ์ด์ก: 8.72B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 105.5M / 100.53M / 4.9% / 28.1% / 9.1%
2409: 96.7M / 91.5M / 5.7% / 23.9% / 1.0%
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: -0.4 / -0.38 / -5.3% / 46.7% / -42.9%
2409: -0.28 / -0.48 / 41.7% / 55.6% / 46.2%
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent...
์๊ฐ์ด์ก: 8.72B
๊ตญ๊ฐ: United States
์ฐ์ : #Medical_Dental_Instruments
์นํฐ: #Health_Care
ํํ์ด์ง: https://www.glaukos.com
- ๋ถ๊ธฐ ๋งค์ถ(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: 105.5M / 100.53M / 4.9% / 28.1% / 9.1%
2409: 96.7M / 91.5M / 5.7% / 23.9% / 1.0%
2406: 95.7M / 88.86M / 7.7% / 19.0% / 11.8%
2403: 85.62M / -- / -- / 15.9% / 4.0%
2312: 82.36M / -- / -- / -- / 5.5%
- ๋ถ๊ธฐ EPS(๊ณต์, ์์ธก, ์ํ, YoY, QoQ)
2412: -0.4 / -0.38 / -5.3% / 46.7% / -42.9%
2409: -0.28 / -0.48 / 41.7% / 55.6% / 46.2%
2406: -0.52 / -0.52 / 0.0% / 23.5% / 36.6%
2403: -0.82 / -- / -- / -13.9% / -9.3%
2312: -0.75 / -- / -- / -- / -19.0%
- ์ฐ๊ฐ ๋งค์ถ(YoY%), EPS(YoY%)
2312: 314.71M(11.3%) / -2.78(-33.0%)
2212: 282.86M(-3.8%) / -2.09(-95.3%)
2112: 294.01M(30.7%) / -1.07(60.4%)
2012: 224.96M(--) / -2.7(--)
#GKOS
- ์ฌ์ ์์ฝ: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent...